Akoya (AKYA) Reports In-Line Q2 EPS, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Morgan Stanley Downgrades Akoya Biosciences Inc (AKYA) to Equalweight
August 6, 2024 12:06 PM EDTMorgan Stanley analyst Tejas Savant downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Overweight to Equalweight with a price target of $3.00 (from $4.00).
The analyst comments "Guide lowered again despite in-line qtr as placements rebound falls short of expectations on weak capital... More
BTIG Downgrades Akoya Biosciences Inc (AKYA) to Neutral
August 6, 2024 6:02 AM EDTBTIG analyst Mark Massaro downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Buy to Neutral.
The analyst comments "AKYA announced its third workforce reduction in 13 months, and lowered its 2024 revenue guidance in back-to-back quarters. Investor concerns have ranged from constrained budgets in the... More
